Idebenone for the treatment of Duchenne muscular dystrophy (Protocol)

Geng J, Dong J, Jiang K, Shen L, Wu T, Ni H, Shi LL, Wang G, Wu H.
The Cochrane Library 2011.
Description of a protocol aiming at assessing efficacy of ibedenone on muscle strength, muscle function, lung function, cardiac function and quality of life for patients with DMD. The MFM is use as primary outcome to assess motor function of patients after 12 months of treatment.

Link

Keywords: Duchenne Muscular Dystrophy, Idebenone, Treatment efficacy, Protocol, Clinical trial

Articles dans les revues scientifiques

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL. BMJ Open. 2018. 30;8(7):e019932.  Protocol of the "SPACE" in wich MFM is used as an outcome measure....

read more